In a recent survey about hybrid trials, over half of respondents reported that hybrid trials are currently more expensive to conduct compared to trials in the traditional model while only one-quarter considered hybrid trials to be less expensive than traditionally run trials. However, there is an expected flip in this sentiment. Two years from now, almost half of respondents expect the hybrid model to be less expensive while only about a quarter think that hybrid trials will be more expensive than traditional trials.
Learn more from our Hybrid/Virtual/Decentralized Clinical Trials Market Outlook report.
Originally published in Life Science Leader.
View Resource